Literature DB >> 27281507

Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands.

E Joline de Groof1, Noortje G M Rossen, Bram D van Rhijn, Evert P M Karregat, Kirsten Boonstra, Ishtu Hageman, Floor Bennebroek Evertsz, Paul J Kingma, Anton H J Naber, Jan H M van den Brande, Rosalie C Mallant-Hent, Marco W Mundt, Geert R A M D'Haens, Cyriel Y Ponsioen.   

Abstract

BACKGROUND: Reported epidemiology and phenotype distributions vary widely and disease burden of inflammatory bowel disease (IBD) is poorly described. Our aim was to establish these features in a population-based cohort covering 319 976 inhabitants. Furthermore, differences between tertiary referral and peripheral hospital patients were quantified.
METHODS: IBD patients in the adherence area of three peripheral hospitals (2004-2012) were included. Medical and surgical treatment data were obtained. Quality of life and disease activity were evaluated. An outpatient cohort from a tertiary referral centre was accrued.
RESULTS: A total of 1461 patients were included: 761 (52.1%) with ulcerative colitis (UC), 579 (39.5%) with Crohn's disease (CD) and 121 (8.3%) with IBD-unspecified. Point prevalence of IBD was 432.1 per 100 000 inhabitants in 2010, which increased significantly over time, P-value of less than 0.0001. The mean annual incidence was 17.2 for UC, 10.5 for CD and 2.2 for IBD-unspecified. Tertiary referral Crohn's patients used thiopurines and biological therapy and underwent surgery significantly more often than patients in peripheral hospitals (P<0.0001). Disease activity correlated negatively with quality of life (P<0.0001) in UC and CD.
CONCLUSION: The prevalence of IBD is still increasing. Burden of disease was significantly more severe, mainly in Crohn's patients, in the referral centre, highlighting the importance of population-based studies to accurately describe phenotype distribution and disease burden.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27281507     DOI: 10.1097/MEG.0000000000000660

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017.

Authors:  Yan Qiu; Wen Ren; Ying Liu; Wei-Er Chen; Xiao-Hua Pan; Jing-Jing Ren
Journal:  EClinicalMedicine       Date:  2020-09-20

2.  Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017).

Authors:  Jesús K Yamamoto-Furusho; Andrea Sarmiento-Aguilar; Joel J Toledo-Mauriño; Katya E Bozada-Gutiérrez; Francisco J Bosques-Padilla; Manuel A Martínez-Vázquez; Virgilio Marroquín-Jiménez; Rosalva García-Figueroa; Christian Jaramillo-Buendía; Rosa M Miranda-Cordero; Jesús A Valenzuela-Pérez; Yolanda Cortes-Aguilar; Janett S Jacobo-Karam; Emilio F Bermudez-Villegas
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

3.  Administration of neem (Azadirachta indica A. Juss) leaf extract decreases TNF-α and IL-6 expressions in dextran sodium sulfate-induced colitis in rats.

Authors:  Riska Habriel Ruslie; Darmadi Darmadi
Journal:  J Adv Vet Anim Res       Date:  2020-12-04

4.  Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study.

Authors:  Ruth Ann Marrie; Lesley Graff; John R Walker; John D Fisk; Scott B Patten; Carol A Hitchon; Lisa M Lix; James Bolton; Jitender Sareen; Alan Katz; Lindsay I Berrigan; James J Marriott; Alexander Singer; Renée El-Gabalawy; Christine A Peschken; Ryan Zarychanski; Charles N Bernstein
Journal:  JMIR Res Protoc       Date:  2018-01-17

5.  Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis.

Authors:  Damián García-Olmo; Gert Van Assche; Ignacio Tagarro; Mary Carmen Diez; Marie Paule Richard; Javaria Mona Khalid; Marc van Dijk; Dimitri Bennett; Suvi R K Hokkanen; Julián Panés
Journal:  Adv Ther       Date:  2019-10-26       Impact factor: 3.845

6.  Cost-effectiveness of Screening Program for Chronic Q Fever, the Netherlands.

Authors:  Pieter T de Boer; Marit M A de Lange; Cornelia C H Wielders; Frederika Dijkstra; Sonja E van Roeden; Chantal P Bleeker-Rovers; Jan Jelrik Oosterheert; Peter M Schneeberger; Wim van der Hoek
Journal:  Emerg Infect Dis       Date:  2020-02       Impact factor: 6.883

7.  Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.

Authors:  R L Goetgebuer; J E Kreijne; C A Aitken; G Dijkstra; F Hoentjen; N K de Boer; B Oldenburg; A E van der Meulen; C I J Ponsioen; M J Pierik; F J van Kemenade; I M C M de Kok; A G Siebers; J Manniën; C J van der Woude; A C de Vries
Journal:  J Crohns Colitis       Date:  2021-09-25       Impact factor: 9.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.